PM Tracker

Forrester healthcare analysts called the shuttering of Amazon Care "a strategic move" rather than a failure. Amazon still has its sights set on primary care, many healthcare experts say, as it represents the gatekeeper of patient care.

At the European Society of Cardiology’s annual meeting, AstraZeneca presented data that could boost Farxiga in the competitive heart failure market. It is the first heart failure drug to show it can reduce the risk of death in patients regardless of their ejection fraction status.

Bayer's anticoagulant to prevent secondary strokes flopped a phase 2 trial, keeping in line with results from rivals BMS and J&J. The company reported that its med, asundexian, did not produce a dose-dependent reduction in the composite rate of covert brain infarction or ischemic stroke.

Compared to traditional implantable defibrillators wired directly to the cardiac muscle, Medtronic's EV ICD system instead connects a single lead underneath the breastbone outside the heart.

This year’s annual meeting of the European Society of Cardiology in Barcelona carried a special spotlight on the growing power of cardiac imaging. We spoke with Alexandra Gonçalves, Philips’ chief medical officer for precision diagnosis, on how tomorrow’s technologies are providing a new view into the leading cause of death worldwide.

A heart pump from Abbott may give at least five years back to severe heart failure patients, according to clinical trial results presented this week at the 2022 European Society of Cardiology Congress in Spain.

A new interim analysis of Bristol Myers Squibb's anticoagulant milvexian as a treatment for secondary strokes shows a mixed bag of data. The drug failed its primary endpoint, but a reduction in stroke incidence among three dosing groups beat the company's expectations.

The expansion, which is pending regulatory approval, will bring Cigna's total ACA footprint to 363 counties across 16 states, the insurer said.

After achieving its main phase 2 trial goal, Alnylam’s immunoglobulin A nephropathy (IgAN) treatment has now hit several secondary endpoints, demonstrating further potential for the Regeneron-partnered therapeutic as the companies aim to catch up to Calliditas Therapeutics' approved med Tarpeyo.

After days of swirling speculation, Olympus finally confirmed this week that it has agreed to sell off its scientific solutions business to Bain Capital Private Equity.

Horizon has submitted a planning application to grow its development and manufacturing facility in Waterford, Ireland. The move, designed to bring on new drug substance biologics development and manufacturing firepower, will add another 320,000 square feet to the plant’s existing 44,000-square-foot fill-finish facility.

CMS is devoting nearly $100 million in grant funding to 59 ACA Navigator organizations, the largest amount ever given to the consumer coverage assistance program.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.